Research Topics
| Sheila M FlemingSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Behavioral phenotypes and pharmacology in genetic mouse models of ParkinsonismSheila M Fleming
Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, California 90095-1769, USA
Behav Pharmacol 17:383-91. 2006..This review discusses the sensitivity of these tests in different genetic mice in addition to their behavioral response to dopamine agonists...- Olfactory deficits in mice overexpressing human wildtype alpha-synucleinSheila M Fleming
Department of Neurology and Neurobiology, The David Geffen School of Medicine at UCLA, 710 Westwood Plaza, Los Angeles, CA 90095 1769, USA
Eur J Neurosci 28:247-56. 2008..Furthermore, the buried pellet and block tests provided sufficient power for the detection of a 50% drug effect, indicating their usefulness for testing novel neuroprotective therapies... - An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidateSheila M Fleming
Department of Psychology, Institute for Neuroscience, University of Texas, Austin, TX 78712, USA
Behav Brain Res 156:201-13. 2005..These data suggest that establishing a symptomatic threshold preclinically may help researchers evaluate potential treatments and model individual and group resistance to nigrostriatal insults... - Variable effects of chronic subcutaneous administration of rotenone on striatal histologyChunni Zhu
Departments of Neurology and Neurobiology, The David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095-1769, USA
J Comp Neurol 478:418-26. 2004.... - Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synucleinSheila M Fleming
Department of Neurology, The Mental Retardation Research Center, The David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1769, USA
J Neurosci 24:9434-40. 2004..These behavioral deficits provide a useful way to assess novel drug therapy in genetic models of synucleinopathies... - A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusionsSheila M Fleming
Departments of Neurology and Neurobiology, The David Geffen School of Medicine at UCLA, 710 Westwood Plaza, Los Angeles, CA 90095 1769, USA
Mol Cell Neurosci 46:597-606. 2011..The data indicate a significant behavioral benefit and a long lasting improvement of ?-synuclein pathology following administration of a short term (2 months) NAP administration in a mouse model of synucleinopathy... - Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synucleinXiao hong Lu
Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California 90095, USA
J Neurosci 29:1962-76. 2009..Our study underscores the need to further explore the putative link between parkin dominant toxicity and PD... - Mice overexpressing corticotropin-releasing factor show brain atrophy and motor dysfunctionsMiriam Goebel
CURE Digestive Diseases Research Center and Center for Neurobiology of Stress, Department of Medicine, David Geffen School of Medicine, UCLA and VA GLA Healthcare System, Los Angeles, CA, USA
Neurosci Lett 473:11-5. 2010.... - Abnormal colonic motility in mice overexpressing human wild-type alpha-synucleinLixin Wang
CURE Digestive Diseases Center and Center for Neurobiology of Stress, David Geffen School of Medicine, University of California at Los Angeles and VAGLAHS, Los Angeles, California, USA
Neuroreport 19:873-6. 2008..These results indicate that Thy1-alphaSyn mice display altered basal and stress-stimulated propulsive colonic motility and will be a useful model to study gut dysfunction associated with Parkinson's disease... - Effects of antioxidants on cancer prevention and neuromotor performance in Atm deficient miceRamune Reliene
Department of Pathology, David Geffen School of Medicine and School of Public Health, UCLA, Los Angeles, CA 90095, USA
Food Chem Toxicol 46:1371-7. 2008..Our short-term study showed that NAC suppressed genome rearrangements linked to cancer. The long-term study demonstrated that NAC reduced the incidence and multiplicity of lymphoma and improved some aspects of motor performance... - Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neuronsYofre Cabeza-Arvelaiz
Department of Pathology and Environmental Health Sciences, The Geffen School of Medicine and School of Public Health, University of California, Los Angeles, 650 Charles E, Young Dr S, CHS 71 295, Los Angeles, CA 90095, USA
Mol Neurodegener 6:83. 2011..Therefore it is of interest to understand how overexpression of SNCA affects neuronal function in regions not directly targeted for neurodegeneration in PD... - Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfectMichael S Levine
Mental Retardation Research Center, The David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Trends Neurosci 27:691-7. 2004.... - Genetic mouse models of parkinsonism: strengths and limitationsSheila M Fleming
Departments of Neurology and Neurobiology, The David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
NeuroRx 2:495-503. 2005..The recent discovery of specific genes causing familial forms of PD has contributed to the development of novel genetic mouse models of PD. This review discusses the validity, benefits, and limitations of these new models... - Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenoneSheila M Fleming
Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1769, USA
Exp Neurol 187:418-29. 2004.... - Cognitive deficits in a mouse model of pre-manifest Parkinson's diseaseIddo Magen
Department of Neurology, The David Geffen School of Medicine at UCLA, 710 Westwood Plaza, Los Angeles, CA 90095 1769, USA
Eur J Neurosci 35:870-82. 2012..With high power to detect drug effects, these anomalies provide a novel platform for testing improved treatments for these pervasive cognitive deficits... - 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's diseaseDong Youn Hwang
Molecular Neurobiology Laboratory, McLean Hospital and Harvard Medical School, Belmont, Massachusetts 02478, USA
J Neurosci 25:2132-7. 2005..Thus, ak mice represent a novel genetic model exhibiting useful characteristics to test the efficacy of symptomatic therapies for PD and to study the functional changes in the striatum after dopamine depletion and L-DOPA treatment... - Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neuronsMatthew S Goldberg
Center for Neurologic Diseases, Harvard Medical School, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Biol Chem 278:43628-35. 2003..Together these findings provide the first evidence for a novel role of parkin in dopamine regulation and nigrostriatal function, and a non-essential role of parkin in the survival of nigral neurons in mice... - Experimental focal ischemic injury: behavior-brain interactions and issues of animal handling and housingTim Schallert
Department of Psychology and Institute for Neuroscience, University of Texas at Austin, USA
ILAR J 44:130-43. 2003..The timing and interaction of biological and motor therapies and the potential contribution of experience-dependent and drug-induced trophic factor expression are discussed... - Should the injured and intact hemispheres be treated differently during the early phases of physical restorative therapy in experimental stroke or parkinsonism?Tim Schallert
Department of Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA
Phys Med Rehabil Clin N Am 14:S27-46. 2003....